Savara Inc.
Quick facts
Phase 3 pipeline
- Molgramostim Open-label · Immunology; Rare/Orphan Diseases
Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production and activation of granulocytes and macrophages to enhance immune function. - Vancomycin inhalation powder · Infectious Disease
Vancomycin inhalation powder works by inhibiting bacterial cell wall synthesis.
Phase 2 pipeline
- Antimycobacterial regimen · Infectious Diseases
Antimycobacterial regimen works by inhibiting the growth of Mycobacterium tuberculosis. - Molgramostim nebulizer solution
Phase 1 pipeline
- AeroVanc · Infectious Disease
Aeruginibactin antibiotic
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Savara Inc.
What is Savara Inc.'s pipeline?
Savara Inc. has 2 drugs in Phase 3, 2 in Phase 2, 1 in Phase 1. Late-stage candidates include Molgramostim Open-label, Vancomycin inhalation powder.
Related
- Sector hub: All tracked pharma companies